Leaders
More
entrepreneurship –
Courageous
transformations
Idorsia has a strong and visionary leadership team, with the power and drive to create more remarkable innovations and more medicines. Our people show up every day with energy, intellect and creativity.
The Idorsia Executive Committee
Date of birth: April 3, 1955
Nationality: Swiss and French
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985; Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997; Founder of Actelion in 1997 and CEO 2000–2017.
Awards: Doctor honoris causa from the University of Basel.
Other Group functions: Member of the Board of Idorsia Ltd, Chairman of the Board of Idorsia Pharmaceuticals Ltd, member of the Board of Idorsia (Shanghai) Pharmaceuticals Co. Ltd.
Other activities and functions: None.
Date of birth: December 27, 1955
Nationality: Swiss and French
Education: MD, specialization in pediatrics and in neonatal intensive care, educated at the University of Nancy, France; further training in physiology and pharmacology at McGill University, Montreal, Canada, and at the University of California, San Francisco, US.
Professional background: Assistant professor, Neonatology; Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche Ltd; Head of Drug Discovery, Pharmacology & Preclinical Development, Actelion (1997–2009); Chief Scientific Officer, Actelion (2009–2017).
Awards: Officer of the Legion of Honour in France; Doctor honoris causa from the Swiss Federal Institute of Technology Lausanne (EPFL); Prix Suisse 2022 awarded by Initiative Switzerland; Doctor honoris causa from the University of Basel.
Other Group functions: None.
Date of birth: November 19, 1956
Nationality: French
Education: MD, pulmonologist and PhD in life science, Paris University, France.
Professional background: Merck Serono, Chief Medical Officer; Serono, Chief Medical Officer International; various executive positions at Astra, Fisons, Rhône-Poulenc Rorer, Glaxo Wellcome, GSK and Chiron; Head of Clinical Development, Actelion (2009–2017), Head of Global Clinical Development, Idorsia (2017–2022).
Other Group functions: Member of the Board of Idorsia Pharmaceuticals Japan Ltd.
Date of birth: March 28, 1960
Nationality: Italian
Education: MD, Pisa University, Italy; Post graduate course in Clinical Pharmacology, Milano University, Italy
Professional background: Various Clinical and Therapeutic Areas leadership positions In Rhone Poulenc Rorer, Novartis, Serono, Merck Serono. Clinical Science Head Actelion (2011-2017), Head of Clinical Development, Actelion /Janssen (2017 -2019), Head of Therapeutic Areas Unit Idorsia (2019 -2022).
Other Group functions: None.
Date of birth: June 23, 1965
Nationality: British
Education: BSc (Hons) in Medical Biochemistry from the University of Birmingham, Birmingham, UK.
Professional background: Various marketing and General Manager positions at GlaxoSmithKline in the UK, US, and Denmark (1995–2012); Global President of Stiefel, a GSK company (2012–2015); Senior VP, Head Global Franchises & Platforms (Pharmaceuticals), GSK (2015–2018).
Other Group functions: Member of the Board of Idorsia Pharmaceuticals Japan Ltd.
Date of birth: October 30, 1963
Nationality: French
Education: Master’s degree in Business Administration from EMLYON Business School, Lyon, France.
Professional background: Held various financial positions at Pierre Fabre SA, an international pharmaceutical and dermo-cosmetic company, serving as Chief Financial Officer from 2002 (1994–2011); Chief Financial Officer, Actelion (2013–2017).
Other Group functions: Member of the Board of Idorsia Pharmaceuticals Ltd, Idorsia (Shanghai) Pharmaceuticals Co. Ltd. and Idorsia Pharmaceuticals Japan Ltd.
Other functions: Member of the Board of Directors of the listed company Carmat SA and the unlisted company Chiron Investments AG.
The Idorsia Leadership Team
Year of birth: 1968
Nationality: Swiss
Education: Master’s degree in Business Administration, Monetary Economics and Corporate Law from the University of Zurich and Chartered Financial Analyst (CFA).
Professional background: Built a deep expertise and network in the area capital markets, while focusing on gaining an understanding for the pharmaceutical and biotechnology market. Stepping stones as sell-side analyst, buy-side analyst and fund manager include: Equity analyst for European Pharmaceuticals at Warburg Dillon Read (1997–1999) and analyst/ fund manager at Julius Baer (2000–2005). Senior financial analyst covering Swiss/European pharmaceutical/biotechnology stocks for Bank Leu (2005), Bank Sarasin (2006) and Bank Vontobel (2007). Team leader for Life Sciences Equity Research at Bank Vontobel (2008–2014). Head of Investor Relations & Corporate Communications for Actelion 2014-2017. Joined Idorsia as Head of Investor Relations & Corporate Communications when the company was established in June 2017.
Year of birth: 1979
Nationality: Swiss
Education: Master of law (LL.M.), University of Cambridge, Trinity Hall, United Kingdom; Lic. iur., University of Fribourg, Switzerland; 2006 Bar admission, Canton of Bern.
Professional background: 2007-2012 Associate in Corporate/M&A team at Homburger AG; 2012-2016 Director Legal (heading Corporate Law), Member of Legal & IP Leadership Team, Group Risk Officer at Lonza AG; 2016-2022 General Counsel, Secretary of the Board and Compliance Officer at Molecular Partners AG.
Other Group functions: Secretary of the Board of Idorsia Ltd., member of Idorsia Pharmaceuticals Ltd Board.
Year of birth: 1978
Nationality: Swiss and Russian
Education: Master degree in Human Resources Management in Russia, Bachelor degree in Finance in Russia; further education and training in Business Administration and Communication in the US (California State University East Bay, Hayward) and in Coaching and Neuro-linguistic Programming in Erickson College, Vancouver, Canada.
Professional background: HR Manager and Organizational Development Manager at British American Tobacco in Russia and in Switzerland 2003-2007; HR Director for Global Clinical Development and Head of Global Talent Acquisition and Development at Actelion 2007-2017. As of 2013 practicing independent professional coach. Joined Idorsia as Head of Human Resources when the company was established in June 2017.
Other Group functions: Member of the Board of Idorsia Pharmaceuticals Japan Ltd.
Year of birth: 1966
Nationality: French
Education: Ph.D. in applied Physico-Chemistry (polymer sciences) in France.
Professional background: 1998–2005. Principal Scientist and Technology Matrix Leader for Parenteral Sustained Delivery systems in the Pharmaceutical Department of Novartis Pharma AG, 2005-2013 CMC project leader at Actelion Pharmaceuticals Ltd, 2013 - 2017 Head Quality Assurance (GMP/GDP) at Actelion Pharmaceuticals Ltd. Joined Idorsia as Head of Pharmaceutical Development when the company was established in June 2017.
Year of birth: 1962
Nationality: Swiss
Education: Doctoral degree. Dr. Phil.II at the University of Basel, Switzerland, further education at Stanford University, School of Medicine, Stanford, CA, US.
Professional background: Research Scientist, Thrombosis Group at Hoffmann-La Roche, 1994-1997. Project Leader “Novel Oral Anticoagulant Project” at Hoffmann-La Roche, 1997-2002. Head of Biology, Axovan Pharmaceutical, 2002-2003. Senior Group Leader, Immunology/Thrombosis Biology at Actelion Pharmaceuticals Ltd, 2003-2016. Head DD Biology, at Actelion Pharmaceuticals Ltd, 2016-2017. Joined Idorsia as Head of Drug Discovery Biology when the company was established in June 2017.
Year of birth: 1967
Nationality: German
Education: PhD in Biochemistry/Life Sciences, Universities of Kaiserslautern and Frankfurt, Msc Toxicology, University of Surrey, UK
Professional background: From 1993 until 2004, various positions in project toxicology/drug development at Sandoz, Ciba and F. Hoffmann-La Roche, 2004-2017 Head of Toxicology, Actelion, since 2011 Head of Preclinical Development, Actelion. Joined Idorsia as Head of Drug Discovery Pharmacology & Preclinical Development when the company was established in June 2017.
Year of birth: 1968
Nationality: Swiss
Education: PhD, synthetic organic chemistry at the University of Bern, Switzerland followed by post-doctoral training at The Scripps Research Institute (TSRI) in LaJolla, California, USA.
Professional background: From 1999 until 2012, various positions of increasing responsibility in Actelion's drug discovery chemistry department contributing to the identification of several lead compounds including macitentan for PAH and daridorexant for insomnia. Senior Group Leader Chemistry Technologies 2012-2017. Joined Idorsia when the company was established in June 2017 as a Senior Group Leader in Drug Discovery Chemistry. Head of Drug Discovery Chemistry at Idorsia since July 2019.
Year of birth: 1970
Nationality: Swiss and German
Education: PhD, organic chemistry at the ETH Zurich, Switzerland.
Professional background: Various positions (Project Chemist, Group Leader, Head GMP production) in R&D and GMP manufacturing at Carbogen-Amcis 1999-2006. Set up fully integrated Chemistry Process R&D at Actelion in 2006. Joined Idorsia when the company was established in June 2017 as Head of Chemical Development, responsible for drug substance development and manufacturing from preclinical phase to launch and commercial supply. Head of Chemical Development and Commercial Manufacturing at Idorsia since July 2019.